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Abstract
It has been recently shown that calcium channel blockers might have a protective effect on cardiac fibrogenesis induced by 
aldosterone. The objective of this study was to evaluate the protective effect of felodipine, a dihydropyridine calcium channel 
blocker, against heart and kidney damage caused by aldosterone-high sodium intake in uninephrectomized rats. Wistar rats 
were divided into three groups: CNEP (uninephrectomized + 1% NaCl in the drinking water, N = 9); ALDO (same as CNEP group 
plus continuous infusion of 0.75 µg/h aldosterone, N = 12); ALDOF (same as ALDO group plus 30 mg·kg-1·day-1 felodipine in 
the drinking water, N = 10). All results were compared with those of age-matched, untreated rats (CTL group, N = 10). After 
6 weeks, tail cuff blood pressure was recorded and the rats were killed for histological analysis. Blood pressure (mmHg) was 
significantly elevated (P < 0.05) in ALDO (180 ± 20) and ALDOF (168 ± 13) compared to CTL (123 ± 12) and CNEP (134 ± 13). 
Heart damage (lesion scores - median and interquartile range) was 7.0 (5.5-8.0) in ALDO and was fully prevented in ALDOF 
(1.5; 1.0-2.0). Also, left ventricular collagen volume fraction (%) in ALDOF (2.9 ± 0.5) was similar to CTL (2.9 ± 0.5) and CNEP 
(3.4 ± 0.4) and decreased compared to ALDO (5.1 ± 1.6). Felodipine partially prevented kidney injury since the damage score 
for ALDOF (2.0; 2.0-3.0) was significantly decreased compared to ALDO (7.5; 4.0-10.5), although higher than CTL (null score). 
Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myo-
cardial necrosis and fibrosis.
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Aldosterone-high salt intake produces a variety of deleteri-
ous actions on the cardiovascular system of uninephrectomized 
rats. Previous studies have shown inflammation and oxidative 
stress within the arteriolar wall of the heart and kidney, and 
inflammatory tissue remodeling (1,2). The histological features 
of malignant or accelerated hypertension have also been 
described in this model (1,3). 
The mechanisms by which aldosterone induces cardiac 
tissue damage are not fully understood and seem to involve 
genomic and non-genomic effects (4). Genomic action is the 
classical mechanism by which aldosterone binds to miner-
alocorticoid receptors (MR) and promotes protein synthesis. 
Non-genomic effects of aldosterone occur within minutes, 
inducing vasoconstriction (5). Also, vascular smooth muscle 
cells from spontaneously hypertensive rats show an increased 
aldosterone-induced non-genomic signaling mediated by c-Src. 
This signaling appears to be important in the profibrotic and 
proinflammatory actions of aldosterone in this genetic model 
of hypertension (6).
Recently, it has been demonstrated that cardiomyocytes 
have putative aldosterone-regulated MR genes (7). Accord-
ingly, the first event leading to cardiovascular inflammation and 
remodeling may be associated with inappropriate MR activation. 
In addition, Dietz et al. (8) have recently reported that dihydro-
pyridine calcium channel blockers (CCBs) have MR antagonist 
activity and that a number of widely used dihydropyridine CCBs, 
including felodipine, compete for aldosterone binding to MR 
and have the effect of MR antagonists on cardiomyocytes. L-
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type calcium channel antagonists are effective in decreasing 
blood pressure and have been shown to be renoprotective. 
However, whether these protective effects are due to blood 
pressure reduction or to a specific pharmacologic blockade is 
still a matter of debate. 
We, therefore, hypothesized that felodipine may protect 
the heart and kidney from damage by decreasing the perivas-
cular inflammation induced by aldosterone-high salt intake 
in uninephrectomized rats. The objective of this study was 
to determine whether felodipine, a dihydropyridine calcium 
channel blocker, is effective in preventing heart and kidney 




Twelve-week-old male Wistar rats (300 ± 20 g) were ob-
tained from the Central Animal Facility of the Botucatu Medical 
School, São Paulo State University, SP, Brazil. The animals 
were housed under standard environmental conditions and 
maintained on a commercial rat laboratory diet (Purina Labina, 
Brazil) and tap water ad libitum. The experimental protocol 
was approved by the Animal Care and Use Committee of our 
Institution and conformed to the NIH Guidelines on the Care 
and Use of Laboratory Animals (Institute of Laboratory Animal 
Research, Commission on Life Sciences, National Research 
Council, 1996). 
Experimental protocol
Laparotomy and unilateral nephrectomy were performed 
under sodium thiopental anesthesia (50 mg/kg, intraperitone-
ally). Immediately after surgery and recovery from anesthesia, 
the rats were randomly divided into three groups as follows: 
CNEP (N = 9) - rats maintained on high NaCl (1%) in the drink-
ing water. ALDO (N = 12) - rats maintained on high NaCl as 
the CNEP group and continuously infused with aldosterone 
(Sigma, USA; 0.75 µg/h), via minipumps implanted subcutane-
ously (Alzet minipumps mod. 2002, Alza Corp., USA). ALDOF 
(N = 10) - same as the ALDO group plus felodipine (30 mg· 
kg-1·day-1) in the drinking water. All results were compared to 
an additional control group of animals that were not unilaterally 
nephrectomized and that did not receive high NaCl, aldosterone 
or felodipine (N = 10).
Tail cuff blood pressure and body weight were recorded 
before and 6 weeks after surgery. At the end of the 6-week 
period, all rats were anesthetized with sodium thiopental (50 
mg/kg, ip) and killed by thoracotomy and blood samples were 
taken from the heart for electrolyte and creatinine measure-
ments. The heart and the remaining kidney were excised and 
weighed. Left and right ventricles were weighed separately. 
Histopathological analysis
The morphometric analysis of the myocardium was per-
formed as described previously (9). Transverse sections of the 
left (LV) and right (RV) ventricles and a sample of the kidney 
were fixed in 10% buffered formalin and embedded in paraffin. 
Five-micron sections of myocardium and kidney were stained 
with hematoxylin-eosin. Also, ventricular sections were stained 
with the collagen-specific stain picrosirius red (sirius red F3BA 
in aqueous saturated picric acid). 
Interstitial myocardial collagen volume fraction (CVF). 
The CVF of the entire section was determined using a Leica 
microscope (objective lens 40X) attached to a video camera 
and connected to a personal computer equipped with image 
analyzer software (Image-Pro Plus 3.0, Media Cybernetics, 
USA). The components of cardiac tissue were identified ac-
cording to their color (i.e., red for collagen fibers, yellow for 
myocytes, and white for interstitial space). The digitized profiles 
were transferred to the computer and CVF was calculated as 
the sum of all connective tissue areas divided by the sum of 
the connective tissue and myocyte areas. On the average, 35 
microscopic fields were analyzed. Perivascular collagen was 
excluded from this analysis. 
Scores of myocardial damage 
Two pathologists blind as to the source of the hematoxylin-
eosin-stained tissue section, independently examined the slides 
and rated the damage using the criteria shown in Table 1. This 
approach emphasized cellular necrosis and inflammatory 
phenomena. Arteriole remodeling was analyzed by calculat-
ing the relative wall thickness (RWT) and relative perivascular 
fibrosis (RPF) as follows: RWT = (WA - LA) / LA, where WA is 
the area of vascular wall, and LA is the lumen area, and RPF = 
(FA - WA) / WA, where FA is the perivascular fibrosis area. 
All analyses were performed using two separate sets of 
vessels as follows: vessels with luminal diameters less than 50 
μm and vessels with lumen diameters between 50-100 μm. At 
least four vessels of each set were measured in all sections and 
only vessels with a circular cross-section were analyzed.
Statistical analysis
Differences among groups were analyzed by one-way 
analysis of variance (ANOVA) followed by pairwise multiple 
comparison (Bonferroni t-test). ANOVA on ranks followed by 
the Dunn test was used to compare scores among groups. 
Spearman’s correlation was used to compare LV and RV 
damage scores and to analyze the association between LV 
or kidney score damage with systolic blood pressure. Differ-
ences were considered to be statistically significant when P 
< 0.05/k, where k is the number of statistical comparisons 
(Bonferroni correction).
Results
Morphometric data and blood pressure results are present-
ed in Table 2. Systolic blood pressure increased in both the 
ALDO and ALDOF groups indicating a non-antihypertensive 
effect of felodipine. Accordingly, both hypertensive groups 
presented increased LV and RV weight. The increase in 
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1.1. Necrosis of few cells +1
1.2. Microinfarction +3
1.3. Infarction (area >0.05 cm2) +5
Note: Frequent lesions (>3 foci) +1
2. Benign vascular damage
2.1. Media hypertrophy +1
2.2. Wall hyalinization (subendothelial) +1
2.3. Arteriolar fibroelastosis +1
Note: Frequent damage (>3 vessels) +1
3. Severe vascular damage
3.1. Transmural fibrinoid necrosis +4
3.2. Myointimal proliferation +4
Note: Frequent damage (>3 vessels) +1
4. Perivascular lesion
4.1. Limited inflammatory infiltrate +1
4.2. Inflammatory infiltrate with perivascular myocyte damage +3
Note: Frequent damage (>3 vessels) +1
Kidney scores
1. Benign vascular damage
1.1. Media layer hypertrophy +1
1.2. Wall hyalinization (subendothelial) +1
1.3. Arteriolar fibroelastosis +1
Note: Frequent damage (>3 vessels) +1
2. Severe arterial damage
2.1. Glomerulonecrosis +4
2.2. Transmural fibrinoid necrosis +4
2.3. Myointimal proliferation +4
Note: Frequent damage (>3 vessels) +1
3. Other lesions
3.1. Acute tubular necrosis +1
Table 2. Morphometric and blood pressure data. 
Group BW (g) SBP (mmHg) LVW/BW (mg/g) RVW/BW (mg/g) CVFLV (%) CVFRV (%)
CTL 389 ± 21a 123 ± 12a 1.82 ± 0.12a 0.61 ± 0.05a 2.9 ± 0.67a 4.0 ± 0.34a
CNEP 414 ± 34a 134 ± 13a 1.85 ± 0.08a 0.60 ± 0.09a 3.4 ± 0.44a 3.6 ± 0.94a
ALDO 399 ± 32a 180 ± 20b 2.51 ± 0.29b 0.69 ± 0.08b 5.1 ± 1.61b 5.6 ± 1.42b
ALDOF 416 ± 29a 168 ± 13b 2.22 ± 0.13c 0.69 ± 0.06b 2.9 ± 0.48a 3.6 ± 0.44a
Data are reported as means ± SD. CTL = control; CNEP = uninephrectomy plus 1% salt in the drinking 
water; ALDO = same as CNEP plus 6-week subcutaneously infused aldosterone; ALDOF = same as 
ALDO plus 6-week oral felodipine; BW = body weight; SBP = systolic blood pressure; LVW = left ven-
tricle weight; RVW = right ventricle weight; CVFLV = collagen volume fraction of left ventricle; CVFRV 
= collagen volume fraction of right ventricle. Means with different superscript letters are significantly 
different (P < 0.05) in all pairwise multiple comparison procedures (ANOVA and Bonferroni t-test).
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CVF that occurred in both ventricles of the ALDO group 
was prevented in the felodipine-treated group.
Serum electrolytes and creatinine data are shown in 
Table 3. Aldosterone infusion increased serum sodium 
level and decreased potassium level, effects that were not 
prevented by felodipine treatment. Conversely, felodipine 
prevented the increase in serum creatinine observed in the 
CNEP and ALDO groups.
Histological alterations in the heart were as follows: 1) 
perivascular inflammatory infiltrate with lymphomononuclear 
cells, including mastocytes, which was associated with 
edema and perivascular myocyte necrosis in ALDO rats 
(Figure 1, panels A and B). This abnormality was rarely 
seen in the ALDOF group; 2) media layer hypertrophy 
in coronary arteries was present in all groups except the 
control group (Figure 2); 3) interstitial lymphomononuclear 
inflammatory infiltrate, including mastocytes, in areas of 
discrete myocyte necrosis. These abnormalities were more 
frequently present in the ALDO group than in the ALDOF 
group; 4) transmural fibrinoid necrosis was observed only in 
the ALDO group. In this case, media layer hypertrophy was 
replaced by arteriolar wall fibrosis (Figure 2, panels E and 
F); 5) areas of myocardial infarction with extensive myocyte 
necrosis, interstitial hemorrhage and polymorphonuclear 
cells. These lesions were either isolated or confluent and 
were found only in the ALDO group. 
Histological alterations in the kidney were as follows: 1) 
acute tubular necrosis plus intensive apoptosis and tubular 
regeneration phenomena. These were present to a greater 
extent in the ALDO group as compared to the ALDOF group; 
2) evidence of malignant hypertension such as arteriolar 
fibrinoid necrosis (Figure 3, panel A), fibrinoid necrosis of 
afferent arterioles and glomerulonecrosis (Figure 3, panel 
B). All animals from the ALDO group presented at least 
one of these lesions. Only two animals from the ALDOF 
group presented some of these lesions; 3) changes sug-
gesting benign hypertension such as muscular media layer 
hypertrophy and arteriolosclerosis were observed in both 
the ALDO and ALDOF groups (Figure 3, panel C). Eight 
of 10 ALDOF animals presented no glomerular damage 
(Figure 3, panel D).
LV vascular remodeling results are presented in Table 
4. For vessels smaller than 50 μm there was an increased 
perivascular fibrosis in the CNEP group. Arterioles with a 
50-100-μm internal diameter showed increased RWT in 
the ALDO and ALDOF groups compared to controls, with 
no statistical difference from CNEP. There was increased 
perivascular fibrosis in the ALDOF group. 
Tissue damage scores are presented for both ventricles 
and the kidney in Figure 4. Both ventricles in the ALDO 
group had the highest score (median and interquartile range: 
LV = 7.0 and 5.5-8.0, RV = 6.5 and 5.0-9.5), compared to 
CNEP (LV = 0.0 and 0.0-0.75; RV = 0.0 and 0.0-1.0) and 
controls (LV = 0.0 and 0.0-1.0, RV = 0.0 and 0.0-0.25). 
Felodipine significantly prevented heart injury as indicated 
Figure 1. Photomicrograph of rat myocardium stained with he-
matoxylin-eosin showing periarteritis in the ALDO group (unine-
phrectomized + 1% NaCl in the drinking water plus continuous 
infusion of 0.75 µg/h aldosterone; Panel A). The square in Panel 
A is presented at higher magnification in Panel B to illustrate the 
lymphomononuclear infiltrate and perivascular myocyte necro-
sis. Bar scale = 20 (Panel A) and 10 μm (Panel B).
Table 3. Plasma sodium, potassium and creatinine levels of the 
groups studied.
Group Na+ (mEq/dL) K+ (mEq/dL) Creatinine (mg/dL)
CTL 143 ± 2.04a 4.80 ± 0.58a 0.65 ± 0.16a
CNEP 154 ± 14.53a/b 5.30 ± 0.42a 1.02 ± 0.08b
ALDO 164 ± 13.20b 3.67 ± 0.11b 1.14 ± 0.33b
ALDOF 153 ± 10.84a/b 3.85 ± 0.53b 0.71 ± 0.04a
Data are reported as means ± SD. Group abbreviations are de-
fined in the legend to Table 2. Means with different superscript 
letters are significantly different (P < 0.05) in all pairwise multiple 
comparison procedures (ANOVA and Bonferroni t-test).
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Figure 2. Photomicrograph of rat myocardium showing no damage in the control group (Panels A and B), arteriolar hypertrophy and 
perivascular fibrosis without inflammation in the CNEP group (uninephrectomized + 1% NaCl in the drinking water; Panels C and D) 
and arteriolar transmural necrosis (arrow) in the ALDO group (uninephrectomized + 1% NaCl in the drinking water plus continuous 
infusion of 0.75 µg/h aldosterone; Panels E and F). Felodipine (ALDOF group) prevented myocardium perivascular damage (Panels G 
and H). Upper and lower panels show hematoxylin-eosin and picrosirius red staining, respectively. Bar scale = 20 μm.
Figure 3. Photomicrograph of a rat kidney from the ALDO group (uninephrec-
tomized + 1% NaCl in the drinking water plus continuous infusion of 0.75 µg/h 
aldosterone) showing arteriolar fibrinoid necrosis (arrow, Panel A), fibrinoid ne-
crosis of afferent arterioles and glomerulonecrosis (arrows, Panel B). Felodipine 
prevented most of the kidney damage in the ALDOF group (Panels C and D). 
Panel C shows muscle layer hypertrophy (arrow) and Panel D shows a typically 
preserved glomerulus (arrow). Bar scale = 20 microns.
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by much lower damage scores compared to ALDO (LV = 1.5 
and 1.0-2.0, RV = 1.0 and 1.0-2.0). Kidney damage scores 
were higher in ALDO (7.5 and 4.0-10.5) compared to controls 
(0.0 and 0.0-0.0) and CNEP (0.0 and 0.0-1.0). Felodipine 
partially prevented kidney injury. The damage scores for the 
ALDOF group (2.0 and 2.0-3.0) were intermediate between 
those for  the CNEP and ALDO groups. However, while 9 of 
the 12 rats in the ALDO group presented at least one area 
of severe vascular damage, such damage was found only 
in 2 of 10 rats in the ALDOF group.
The LV and RV damage scores in the ALDO group 
were closely associated (R = 0.838, P < 0.001; Spearman’s 
correlation). There was no significant association between 
kidney and myocardial damage scores or between systolic 
blood pressure and tissue injury.
Discussion
We have demonstrated that felodipine given to aldos-
terone-high salt uninephrectomized rats prevents arterial 
inflammation, myocyte necrosis, myocardial fibrosis, and 
renal dysfunction.
Aldosterone-high salt-induced hypertension and myo-
cardial and renal damage have been demonstrated by 
several groups of investigators (1,2,10,11). Also, the pro-
tective effects of angiotensin-converting enzyme inhibitors 
and AT1, mineralocorticoid and endothelin receptor blockers 
have been shown to be independent of blood pressure (12-
14). These results suggest that aldosterone-salt-induced 
hypertension depends on multiple factors, including vaso-
constriction and volume overload, and therefore would not 
be expected to be prevented by just one class of drugs.
Dihydropyridines, calcium channel blockers, are often 
used to treat arterial hypertension. A number of widely 
used dihydropyridine are able to inhibit the activation of 
MR. They have varied degrees of effect on MR and nimo-
dipine and felodipine are the most potent MR inhibitors. 
Dihydropyridine may compete with aldosterone for binding 
Figure 4. Box-plot showing the damage score for the left (LV) and right (RV) ventricles (Panels A and B) and the kidney (Panel C). 
Myocardial injury but not kidney injury induced by aldosterone/salt was fully prevented by felodipine. *P < 0.05 vs controls (CTL), 
CNEP and ALDOF; #P < 0.05 vs controls (ANOVA on ranks and the Dunn test). + = values exceeding the box-plot boundaries; CNEP 
= uninephrectomized plus 1% NaCl in the drinking water; ALDO = same as CNEP plus continuous infusion of 0.75 µg/h aldosterone; 
ALDOF = same as ALDO plus continuous infusion of 30 mg·kg-1·day-1 felodipine.
Table 4. Left ventricular coronary artery remodeling data. 
Arterioles (<50 µm) Arterioles (50-100 µm)
Group RWT RPF RWT RPF
CTL 0.68 ± 0.110a 0.32 ± 0.103a 0.46 ± 0.13a 0.21 ± 0.067a
CNEP 0.66 ± 0.110a 0.39 ± 0.094b 0.53 ± 0.089a/b 0.26 ± 0.073a/b
ALDO 0.69 ± 0.085a 0.39 ± 0.144a/b 0.58 ± 0.091b 0.21 ± 0.097a
ALDOF 0.69 ± 0.110a 0.36 ± 0.121a/b 0.59 ± 0.095b 0.29 ± 0.064b
Data are reported as means ± SD. Group abbreviations are defined in the legend to Table 
2. RWT = relative wall thickness; RPF = relative perivascular fibrosis. Means with different 
superscript letters are significantly different (P < 0.05) in all pairwise multiple comparison 
procedures (ANOVA and Bonferroni t-test).
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and block aldosterone-induced co-activator recruitment to 
MR (8). The aldosterone-induced MR is primarily inhibited 
by steroidal MR antagonists such as eplerenone, canreno-
ate and spironolactone. Therefore, there is evidence that 
CCBs and aldosterone antagonists may have a common 
pathway concerning the beneficial effect of MR inhibition. 
Eventually, association of both drug classes might amelio-
rate arterial hypertension and prevent cardiac and kidney 
remodeling.
In this study in rats, felodipine (30 mg/kg) induced only 
a slight nonsignificant reduction of blood pressure and is 
therefore considered to be ineffective for antihypertensive 
treatment in this experimental model of hypertension. On 
the other hand, hypernatremia was partially prevented and 
hypokalemia following hyperaldosteronism was not modi-
fied by felodipine treatment. Dietz et al. (8) demonstrated 
that nimodipine, a dihydropyridine CCB, inhibited in vivo 
aldosterone-induced EnaCγ expression in the distal colon 
of nephrectomized rats. This suggests that this class of 
CCB would act in vivo as an MR antagonist. In humans, 
felodipine was reported to reverse the sodium retention 
induced by exogenous angiotensin II (15). Therefore, it is 
reasonable to suspect that our findings are related to the 
MR antagonism effect of felodipine and we may assume 
that felodipine increases sodium urinary loss and does not 
modify potassium excretion.
Interestingly, increased creatinine was found in the 
ALDO and CNEP groups, indicating that renal dysfunction 
was due to the uninephrectomy and salt overload state 
rather than to the hyperaldosteronism. The protective effect 
of felodipine agrees with data reported by Francischetti et 
al. (16) who demonstrated improved glomerular dynamics 
in hypertensive rats receiving felodipine. The authors con-
sidered this to be the result of nephrosclerotic prevention. 
Herein a similar positive finding was obtained in the absence 
of blood pressure normalization. 
Recently, Fan et al. (17) showed kidney injury charac-
terized by glomerular cell proliferation and renal interstitial 
fibrosis in this model of hypertension. Administration of the 
CCB azelnidipine attenuated the morphological changes 
of the kidneys. Our data are consistent with these results, 
indicating that dihydropyridine may elicit amelioration of 
aldosterone-induced kidney injury in uninephrectomized 
rats receiving 1% NaCl in the drinking water.
The myocardial hypertrophy and fibrosis, as well as 
perivascular and interstitial inflammation, observed in the 
ALDO group agreed with several other studies. 
The mechanisms underlying myocardial fibrosis in 
aldosterone-salt hypertensive rats remain a matter of 
debate. Robert et al. (18) described increased myocardial 
collagen synthesis in aldosterone-high salt rats only 15 days 
after the beginning of aldosterone infusion, even though the 
plasma level of aldosterone was increased on the first day 
of infusion. The authors interpreted their results as evidence 
that the aldosterone-induced fibrosis is an indirect effect, 
which would involve cellular necrosis. This would imply that 
aldosterone-salt-induced myocardial fibrosis is a reparative 
rather than a reactive process.
Our results also indicate that interstitial fibrosis in the 
ALDO group was a consequence of cellular damage, since 
prevention of inflammation and necrosis was associated with 
the absence of an abnormal accumulation of myocardial 
collagen. Also of relevance is the clear association between 
myocardial necrosis and vascular injury that accounts for 
the presence of ischemic myocardial necrosis in both ven-
tricles. Others have suggested a similar mechanism (19). 
In the present study, the myocardial histological analysis 
identified at least three possible mechanisms of tissue 
damage, as follows: 1) a consequence of inflammation in 
the perivascular area; 2) secondary to ischemia if coronary 
arterioles were damaged enough to jeopardize the blood 
supply, and 3) a consequence of a lymphomononuclear 
infiltrate, including mastocytes, in interstitial vessels or 
of myocarditis foci. The cause of a lymphomononuclear 
infiltrate in the absence of cellular necrosis is not clear. 
However, several studies (1,19-22) have shown a blood 
pressure-independent association between inflammation 
and MR activation via the stimulation of immunocompetent 
cells. Monocyte-derived macrophages, rich in nicotinamide-
adenine-dinucleotide phosphate (NADPH) oxidase, amplify 
the generation of reactive oxygen species (ROS) (23). 
ROS may also be generated by aldosterone-salt via MR 
activation. ROS production is associated with intracellular 
calcium elevation, protein kinase C activation and NADPH 
oxidase activation, creating a vicious cycle of inflammation 
and progressive necrosis and fibrosis (24). 
Accordingly, the protective effect of felodipine would 
occur by anti-inflammatory and/or vasodilator actions 
resulting from an antagonizing action on either the MR or 
L-type calcium channels. Both mechanisms would lead 
to decreased levels of end products of lipid peroxidation, 
free radicals and hydroperoxides and to increased total 
antioxidant capacity (25). In the present study, significant 
vasodilation did not occur since arterial blood pressure 
remained elevated. 
Our results show that felodipine prevented perivascular 
and interstitial inflammation and interstitial fibrosis in rats 
despite the presence of arterial hypertension and myocardial 
hypertrophy. Research with mibefradil, a T- and L-type CCB, 
has shown that the drug prevented myocardial fibrosis, 
although inflammation and necrosis were not assessed 
(26). Mibefradil, but not amlodipine, prevented glomerular 
damage in DOCA-salt hypertensive rats (27). Therefore, 
our findings, together with those of others, suggest that the 
effects of CCBs are drug class-dependent.
The heterogeneity of damage intensity from animal 
to animal is noteworthy. While several animals presented 
very extensive damage to the heart and/or kidney, oth-
ers had only slight damage, which could be attributed to 
hypertension. Although this aspect is not highlighted in 
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the literature, it suggests that aldosterone-induced tissue 
damage clearly depends on the individual’s response. We 
did not find a significant correlation between systolic blood 
pressure and either the kidney or the myocardial damage 
score in agreement with previous findings (28), suggesting 
a hypertension-independent mechanism for perivascular 
inflammation and myocardial necrosis.
In the present study, kidney and heart damage was 
analyzed in the same rat receiving an aldosterone-high 
salt diet. The results indicated that the presence of severe 
injury to the heart did not always indicate damage to the 
kidney or vice versa. This observation suggests that the 
physiological control and response to injury may differ 
depending on the target organ. 
The distinct patterns of remodeling in large and small 
arterioles suggest a coronary vascular selectivity associ-
ated with this experimental model. Interestingly, coronary 
arteriole remodeling was not prevented by felodipine and 
occurred in the absence of hypertension and inflammation, 
indicating a reactive process induced by high salt intake in 
the perivascular area. This remodeling may not require a 
high level of circulating aldosterone and may involve a local 
synthesis induced by high sodium (29). In normotensive 
WKY rats, a high salt diet alone has been shown to cause 
myocardial perivascular fibrosis (30). Normotensive rats fed 
a high salt diet underwent renal vascular and glomerular 
remodeling (31) and showed depressed reactivity to dilator 
agonists (32). Therefore, it is reasonable to assume that 
reactive perivascular fibrosis induced by high salt intake 
would cause a decreased coronary flow reserve and sec-
ondary myocardial remodeling.
The lack of increased perivascular fibrosis in the ALDO 
group could be explained by the marked exudative process 
still taking place at the end of the experiment. More than 
likely, a longer study period would have revealed a repara-
tive process with increased fibrosis.
We have shown that felodipine has a protective effect 
on the myocardium and kidney as indicated by decreased 
perivascular inflammation and myocardial necrosis and 
fibrosis in aldosterone-high salt intake-hypertensive rats. 
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